Top Markets
Coin of the day
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

COEP
주식 순위 #28025
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates... Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
주가
$4.81
마지막 동기화: 2026-07-27
시가총액
$29.01M
변동 (1일)
-8.56%
변동 (1년)
-64.66%
국가
US
거래 Coeptis Therapeutics Holdings, Inc. (COEP)

카테고리

Coeptis Therapeutics Holdings, Inc. (COEP)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Coeptis Therapeutics Holdings, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Coeptis Therapeutics Holdings, Inc.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH